AstraZeneca looks to China for kidney disease R&D

AstraZeneca ($AZN) has struck up a partnership with the Shenzhen University Health Science Center to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China's aging population. Under the deal, the two will focus on diabetic nephropathy, and AstraZeneca said the partnership is part of its efforts to stand up a product-generating operation in the country. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.